Soluble factors that promote survival and differentiation of glia and neurons during development are likely to play key roles in neurodegeneration and demyelinating diseases such as multiple sclerosis (MS) and have the potential to be important therapeutic targets. We examined the effect of TrkB signaling and the expression patterns of neurotrophic and gliotrophic factors in the mouse brain in MOG-induced experimental allergic encephalomyelitis (EAE). With induction of mild disease, TrkB heterozygous mice were more severely affected compared to their wild type littermates. However, with more potent disease induction, TrkB heterozygotes fared similar to their wild type littermates, suggesting complex modulatory roles for TrkB signaling. One possible explanation for this difference is that the expression patterns of neurotrophic factors correlate with disease severity in individual mice with mild disease, but not in more severe disease. With the less potent induction in C57BL/6 mice, we found that BDNF was consistently increased at EAE onset, while the soluble gliotrophic factor neuregulin (NRG1) was increased only in the chronic phase of the disease. Treatment of these animals with glatiramer acetate (GA) to decrease disease severity resulted in lower levels of both BDNF and NRG1 expression in some mice at 35 days after immunization compared to those in untreated EAE mice, but had no direct effect on these factors in the absence of EAE. Our results suggest a complex interplay between neurotrophic and gliotrophic factors in EAE that is dependent on disease stage and severity. While signaling by BDNF through TrkB is protective in mild disease, this effect was not seen in more severe disease. The late induction of NRG1 in the chronic stage of disease could also worsen disease severity through its known ability to activate microglial, inflammatory pathways. While complex, these studies begin to define underlying axoglial trophic activities that are likely involved in both disease pathogenesis and repair.
Soluble factors that promote survival and differentiation of glia and neurons during development are likely to play key roles in neurodegeneration and demyelinating diseases such as multiple sclerosis (MS) and have the potential to be important therapeutic targets. We examined the effect of TrkB signaling and the expression patterns of neurotrophic and gliotrophic factors in the mouse brain in MOG-induced experimental allergic encephalomyelitis (EAE). With induction of mild disease, TrkB heterozygous mice were more severely affected compared to their wild type littermates. However, with more potent disease induction, TrkB heterozygotes fared similar to their wild type littermates, suggesting complex modulatory roles for TrkB signaling. One possible explanation for this difference is that the expression patterns of neurotrophic factors correlate with disease severity in individual mice with mild disease, but not in more severe disease. With the less potent induction in C57BL/6 mice, we found that BDNF was consistently increased at EAE onset, while the soluble gliotrophic factor neuregulin (NRG1) was increased only in the chronic phase of the disease. Treatment of these animals with glatiramer acetate (GA) to decrease disease severity resulted in lower levels of both BDNF and NRG1 expression in some mice at 35 days after immunization compared to those in untreated EAE mice, but had no direct effect on these factors in the absence of EAE. Our results suggest a complex interplay between neurotrophic and gliotrophic factors in EAE that is dependent on disease stage and severity. While signaling by BDNF through TrkB is protective in mild disease, this effect was not seen in more severe disease. The late induction of NRG1 in the chronic stage of disease could also worsen disease severity through its known ability to activate microglial, inflammatory pathways. While complex, these studies begin to define underlying axoglial trophic activities that are likely involved in both disease pathogenesis and repair.
© 2013 Elsevier B.V. All rights reserved.
Introduction
Based on the efficacy of immunomodulatory therapies in patients with MS, much of the research and thinking about pathogenesis and treatment have traditionally focused on suppressing or modulating the immune system. One of the most successful therapeutic strategies in combating this disorder is a mixture of basic peptides, randomly synthesized at specific molar ratios, called glatiramer acetate (GA) (Ragheb et al., 2001; Kieseier and Stuve, 2011; Lalive et al., 2011; Racke and Lovett-Racke, 2011) . Recent reports suggest that in addition to its immunoregulatory anti-inflammatory effects, GA may also have neuroprotective effects and that this protection may be conferred through the local expression of neurotrophic factors such as BDNF in the brain (Aharoni et al., 2005) . BDNF is involved in neuronal survival, differentiation, and function, as well as glial development in the central nervous system (CNS) (Chao, 2003) . BDNF and its receptor truncated TrkB tyrosine kinase receptor (gp145trkB) were found in lesions of MS patients (Stadelmann et al., 2002) and also in EAE (Aharoni et al., 2005; De Santi et al., 2009; Colombo et al., 2012) . The therapeutic effect of GA was reported previously to have neuroprotective effects with the potential to modulate BDNF expression in the diseased brain (Aharoni et al., 2005) . The most recent report from Lee et al. (2012) indicates that the CNS damage is increased in the early stages of the disease when BDNF is lacking, but there was no significant effect in later stages of the disease.
Recent studies have rekindled the notion that neurological dysfunction in patients with MS relates best to the degree of neuronal (axonal) and glial damage (Loeb, 2007; Ilieva et al., 2009; Amor et al., 2010; Derfuss et al., 2010; Siffrin et al., 2010) . Therefore, to understand the pathogenesis of MS and to develop biologically targeted therapeutics, a greater understanding of axoglial biology is needed in the context of inflammatory modulation. In addition to neurotrophic factors, such as BDNF, central to axoglial biology are protein regulatory factors that signal in the opposite direction, from neurons to glia, and are referred to as "gliotrophic" factors. One of these is called neuregulin derived from the neuregulin1 gene (NRG1) that is important for peripheral
